Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Milosevic, Jelena ^a   Klinge, Johanna ^a   Borg, Anna Lena ^a   Foukakis, Theodoros ^a   Bergh, Jonas ^a,b   Tobin, Nicholas P ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DISEASE MARKER; GENETIC SIMILARITY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MCF-7 CELLS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84885335453     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-473     Document Type: Article

References (40)

1. Jordan VC. The ups and downs of the estrogen receptor. J Clin Oncol 2003, 21:3-4. 10.1200/JCO.2003.10.008, 12506162.
2. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001, 93:1714-1723. 10.1093/jnci/93.22.1714, 11717332.
3. Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003, 72:877-883. 10.1016/S0024-3205(02)02305-6, 12493568.
4. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005, 23:1616-1622. 10.1200/JCO.2005.10.036, 15755967.
5. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998, 51:227-238. 10.1023/A:1006132427948, 10068081.
6. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987, 51:941-951. 10.1016/0092-8674(87)90581-2, 3690665.
7. Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 2006, 12(3 Pt 2):1013s-1018s.
8. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006, 13(Suppl 1):S15-S24.
9. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 2007, 13:1950-1954. 10.1158/1078-0432.CCR-06-2540, 17404074.
10. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003, 95:142-153. 10.1093/jnci/95.2.142, 12529347.
11. Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G. Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 2011, 11:417. 10.1186/1471-2407-11-417, 3192789, 21955753.
12. Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J. When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol 2012, 23(10):349-353.
13. Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 Are unstable throughout tumor progression. J Clin Oncol 2012, 30:2601-2608. 10.1200/JCO.2011.37.2482, 22711854.
14. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518. 10.1200/JCO.2009.23.1274, 19949017.
15. Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 1996, John Wiley & Sons, Ltd.
16. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S, Yue W. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 2002, 193:29-42. 10.1016/S0303-7207(02)00093-X, 12160999.
17. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003, 278:30458-30468. 10.1074/jbc.M305226200, 12775708.
18. Yue W, Wang JP, Conaway MR, Li Y, Santen RJ. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 2003, 86:265-274. 10.1016/S0960-0760(03)00366-2, 14623520.
19. Yue W, Wang JP, Conaway M, Masamura S, Li Y, Santen RJ. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 2002, 143:3221-3229. 10.1210/en.2002-220186, 12193533.
20. Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007, 106:102-110. 10.1016/j.jsbmb.2007.05.008, 2147683, 17616457.
21. Al Saleh S, Al Mulla F, Luqmani YA. Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS One 2011, 6:e20610. 10.1371/journal.pone.0020610, 3119661, 21713035.
22. Chan CM, Martin L-A, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002, 81:333-341. 10.1016/S0960-0760(02)00074-2, 12361723.
23. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Investig 2010, 120:2406-2413. 10.1172/JCI41680, 2898598, 20530877.
24. Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010, 29:6071-6083. 10.1038/onc.2010.333, 20711236.
25. Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A. " Go or grow" : the key to the emergence of invasion in tumour progression?. Math Med Biol 2010, 29:49-65.
26. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 2007, 17:813-826. 10.1097/FPC.0b013e32820b853a, 17885619.
27. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998, 139:4164-4174. 10.1210/en.139.10.4164, 9751496.
28. Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang T-L, Gyorffy B, Lupien M. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA 2013, 110:E1490-E1499. 10.1073/pnas.1219992110, 23576735.
29. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2011, 30:587-592.
30. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res 2010, 12:R92. 10.1186/bcr2771, 3046433, 21059212.
31. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2011, 30:593-599. 3295557, 22124109.
32. Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res 2012, 14:R78. 10.1186/bcr3191, 3446341, 22608253.
33. Chen J, Imanaka N, Chen J, Griffin JD. Hypoxia potentiates notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 2009, 102:351-360. 2816657, 20010940.
34. Bolos V, Mira E, Poveda BM, Luxan G, Canamero M, Martinez-A C, Manes S, de la Pompa JL. Notch activation stimulates migration of breast cancer cells and promotes tumor growth. Breast Cancer Res 2013, 15:R54. 10.1186/bcr3447, 23826634.
35. Scherbakov AM, Andreeva OE, Shatskaya VA, Krasil'nikov MA. The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J Cell Biochem 2012, 113:2147-2155. 10.1002/jcb.24087, 22307688.
36. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005, 23:7721-7735. 10.1200/JCO.2005.09.004, 16234531.
37. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003, 17:575-588. 10.1210/me.2002-0318, 12554765.
38. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001, 61:8452-8458.
39. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001, 61:5771-5777.
40. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (faslodex). Endocrinology 2001, 142:2776-2788. 10.1210/en.142.7.2776, 11415996.